Prevalence of Cancer Survivors in 2019 Among Patients Diagnosed Between 1975 and 2019: A Population‐Based Study in Japan
Cancer Medicine · 2026-06 · 15 (6)
DOI: 10.1002/cam4.72012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 04.06.2026. Verfasst von Haruka Kudo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Control Center, Osaka International Cancer Institute, Osaka, Japan. Hauptthemen laut MEDLINE: Neoplasms, Cancer Survivors. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ministry of Health, Labour and Welfare, Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Owing to improved prognosis, cancer survivors are a growing population; however, little is known about their prevalence in Asian countries. This study estimated the prevalence and characteristics of cancer survivors in Japan, including long‐term survivors. Using data from the Osaka Cancer Registry, which covers 8.8 million residents in Osaka Prefecture, Japan, we identified individuals diagnosed with cancer between 1975 and 2019 who were alive in 2019. Cancer prevalence was calculated as the number of patients alive in 2019, stratified by sex, age in 2019, time since diagnosis, and 22 cancer types. National estimates were obtained by applying sex‐ and age‐specific prevalence proportions in Osaka to the Japanese population. In 2019, 461,489 cancer survivors were living in Osaka Prefecture (5.4% of the prefectural population; 5221 per 100,000). Most were older adults, with 83% of males ( n = 188,881) and 70% of females ( n = 163,331) aged ≥ 65 years in 2019. Long‐term survivors (≥ 10 years after diagnosis) comprised 34% of all survivors. These patterns varied across cancer types. Nationally, an estimated 6.9 million individuals (5.5% of the national population) lived after a cancer diagnosis. Based on 44 years of follow‐up data, our findings highlighted a substantial subgroup of cancer survivors requiring long‐term treatment, follow‐up care, and age‐specific support. These findings may provide useful insights for healthcare planning and cancer survivor policies in aging societies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cancer Control Center, Osaka International Cancer Institute, Osaka, Japan.
ORCID-Profile: Toshitaka Morishima
Förderung
- Ministry of Health, Labour and Welfare
- Japan Society for the Promotion of Science
Zitieren
APA
Kudo, H., Nakata, K., Kishimoto, K., Ikawa, T., Iwaki, Y., Kuwabara, Y., Morishima, T., & Miyashiro, I. (2026). Prevalence of Cancer Survivors in 2019 Among Patients Diagnosed Between 1975 and 2019: A Population‐Based Study in Japan. Cancer Medicine, 15(6). https://doi.org/10.1002/cam4.72012
Vancouver
Kudo H, Nakata K, Kishimoto K, Ikawa T, Iwaki Y, Kuwabara Y, et al. Prevalence of Cancer Survivors in 2019 Among Patients Diagnosed Between 1975 and 2019: A Population‐Based Study in Japan. Cancer Medicine. 2026;15(6). doi:10.1002/cam4.72012
BibTeX
@article{Kudo2026,
author = {Kudo, Haruka and Nakata, Kayo and Kishimoto, Kenji and Ikawa, Toshiki and Iwaki, Yoko and Kuwabara, Yoshihiro and Morishima, Toshitaka and Miyashiro, Isao},
title = {Prevalence of Cancer Survivors in 2019 Among Patients Diagnosed Between 1975 and 2019: A Population‐Based Study in Japan},
journal = {Cancer Medicine},
year = {2026},
volume = {15},
number = {6},
doi = {10.1002/cam4.72012}
}
EUVIMED